Healthcare technology company Symplr, backed by Clearlake Capital, is in the midst of a single-asset secondaries deal, PE Hub reports. The secondaries process comes after Symplr returned to market earlier this year with Evercore, Goldman Sachs and William Blair exploring transactions including a stake sale, as PE Hub reported in June. Charlesbank made a minority investment in Symplr in a deal that valued the company in the range of $3.3 billion to $3.5 billion. Read more.
Symplr Pursues Single-Asset Secondaries Sale
